Clinical Trials Browser

Interventional × patritumab deruxtecan × Breast × Clear all

NCT07060807 2026-04-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase 2 Recruiting

Breast Neoplasms

NCT05865990 2026-03-12

TUXEDO-3

Phase 2 Active not recruiting

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04965766 2025-12-23

ICARUS BREAST

Phase 2 Recruiting

Breast Neoplasms

NCT04699630 2025-12-22

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02980341 2024-10-30

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Phase 1/2 Completed

182 enrolled 37 charts

Breast Neoplasms, Neoplasms

NCT06298084 2024-03-29

ICARUSBREAST02

Phase 1/2 Recruiting

Breast Cancer Metastatic

NCT05569811 2023-09-21

VALENTINE

Phase 2 Active not recruiting

Breast Neoplasms

NCT04610528 2023-06-23

TOT-HER3

Phase EARLY_PHASE1 Unknown

Breast Neoplasms